|
Home | Medical-Newswire.Com:
|
(EMAILWIRE.COM, May 22, 2012 ) New York, NY -- Shares of NovaBay Pharmaceuticals (NBY) may have significant room to move higher, according to VFC's Stock House, an information and research outlet that brings ideas and opens discussions to a broad spectrum of investors.
With a science that could potentially replace common antibiotics, against which a large part of the population is already resistant, NBY's proprietary technology alone could be worth more than the current market cap.
Shares of NovaBay Pharmaceuticals (NBY) were cruising along for months in a price range pretty much centered at right around the $1.30 mark until a sudden slide took shape along as the general market started to experience an overall downturn. No news hit the streets to justify the share price drop and volume, while above the norm, did not indicate a mass exodus of any sort.
Once the short term dust settled, however, NovaBay shares were quick to regain the one dollar foothold when news hit the wires last week announcing that the company had enrolled its first patient in a Phase IIb study that will evaluate the Company's lead compound, NVC-422, in the treatment of adenoviral conjunctivitis, a highly contagious form of "pink eye."
The initiation of this trial, entitled BAYnovation, and the enrollment of the first patient should be viewed as a significant milestone for NovaBay, as there is currently no treatment for viral conjunctivitis on the market. The company is also working closely with the FDA to ensure that all guidelines and criteria are met to ensure the most efficient compilation of data in preparation for achieving the goal of commercialization as quickly as possible.
Antibiotic resistance is one of the medical communities growing concerns, and has even been labeled as a crisis by some in the field. The ever-increasing cases of resistance are threatening to become a growing financial burden on the global health care system at a time when governments and professionals are looking to cut costs. Additionally, lives could be at risk as a result of this dilema, as patients may have no immediate answer to fast-spreading infection as a result of the resistance to antibiotics.
The Centers for Disease Control and Prevention has even chimed in, warning of a pending crisis on its website and stating that, "These drugs have been used so widely and for so long that the infectious organisms the antibiotics are designed to kill have adapted to them, making the drugs less effective. People infected with antimicrobial-resistant organisms are more likely to have longer, more expensive hospital stays, and may be more likely to die as a result of the infection."
NovaBay's Aganocide technology, which forms the basis of NVC-422, inherently mimics a body's own defense system by acting as white blood cells do, which greatly reduces the risk of resistance to treatment. With that in mind, and considering the pipeline potential should already-recognized positive results be repeated through late stage trials, NBY may be hugely undervalued as a speculative play moving forward.
For full article visit: http://vfcsstockhouse.com/blog/article/-novabay-s-nby-market-cap-is-not-adequately-valuing-pipeline-potential
For full report and opinion visit: http://vfcsstockhouse.com/blog/article/-the-facebook-fb-ipo-don-t-believe-the-hype
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
About VFCsStockHouse.com:
VFC's Stock House is an information and research outlet that brings new ideas to the table and opens discussions for a broad spectrum of investors, with a strong focus on - but not limited to - biotech stocks and the pharmaceutical and healthcare sectors. VFC's Stock House provides individual company profiles, write-ups and reports as well as giving general insights into broader-market news through various 'Stock Watch' lists. At the conclusion of most weeks, VFC's Stock House issues a "Weekly Stock Watch" that examines news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. The information contained within the pages of VFC’s Stock House are not intended to be taken as advice, but as a starting point where investors can follow up with their own DD and devise their own entry and exit strategies.
For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
VFC
240-786-2111
vfc@vfcsstockhouse.com 
Source: EmailWire.com
|
|
|
|
